Will Transcatheter Repair Be an Option for Patients with Severe Tricuspid Regurgitation?

Edge-to-edge tricuspid valve repair was safe and improved quality of life, compared with medical therapy, but did not reduce death or hospitalization for heart failure.

Treatment options for patients with severe, symptomatic tricuspid regurgitation (TR) are currently limited to medical therapy (diuretics) and surgery, which is only rarely offered. Transcatheter edge-to-edge repair (TEER) with a clip can reduce TR and was compared with medical therapy alone in a randomized trial funded by the device maker (NCT03904147).

Of the 350 randomized patients (mean age, 78 years; 55% women), 94% had functional TR (90% with atrial fibrillation) and 25% had been hospitalized for heart failure in the year before enrollment. The median length of stay was 1 day, and no in-hospital deaths occurred, although 7% of clips detached from a single leaflet without adverse sequelae.

The primary hierarchical composite endpoint — dea…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)